Deutsche Bank hikes AstraZeneca target price despite rising rate environment
6th Apr 2022 11:07
(Sharecast News) - Analysts at Deutsche Bank hiked their target price for shares of AstraZeneca, telling clients they saw no reason to tilt towards so-called 'value' names in the space and away from 'growth'.
Read moreAstraZeneca's Ondexxya receives Japanese approval
29th Mar 2022 07:14
(Sharecast News) - Drugmaker AstraZeneca revealed on Tuesday that its Ondexxya asset had become the first approved medicine in Japan to specifically reverse the anticoagulant effect of Factor Xa inhibitors, providing "a major advance" in the treatment of patients hospitalised with life-threatening bleeding.
Read moreAstraZeneca Covid drug gets EU approval
28th Mar 2022 07:19
(Sharecast News) - The European Union has given marketing approval to AstraZeneca's Evusheld coronavirus medicine for adults and children over 12 years old, the company said on Monday.
Read moreAstraZeneca's Imfinzi shows no major cervical cancer benefit
24th Mar 2022 08:13
(Sharecast News) - AstraZeneca said its Imfinzi treatment did not produce a significant improvement for cervical cancer patients over treatment by chemoradiotherapy (CRT) on its own.
Read moreAstraZeneca enters into settlement agreement with Chugai Pharmaceutical
17th Mar 2022 07:58
(Sharecast News) - Drugmaker AstraZeneca's rare disease unit has entered into a settlement agreement with Chugai Pharmaceutical, resolving all patent disputes between the two companies related to long-acting C5 complement inhibitor, Ultomiris (ravulizumab).
Read moreAstraZeneca's Lynparza candidate gets green light from FDA
14th Mar 2022 07:37
(Sharecast News) - Drugmaker AstraZeneca said on Monday that Lynparza candidate had been approved in the US as an adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer.
Read moreAstraZeneca strikes global collaboration and licence agreement with Neurimmune
1st Mar 2022 07:51
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its rare diseases subsidiary had closed an exclusive global collaboration and licence agreement with Neurimmune for NI006, an investigational human monoclonal antibody currently in Phase Ib development.
Read moreAstraZeneca strikes global collaboration and licence agreement with Neurimmune
1st Mar 2022 07:51
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its rare diseases subsidiary had closed an exclusive global collaboration and licence agreement with Neurimmune for NI006, an investigational human monoclonal antibody currently in Phase Ib development.
Read moreAstraZeneca chair to step down next year
22nd Feb 2022 12:21
(Sharecast News) - AstraZeneca chair Leif Johansson is to retire next year, it was announced on Tuesday, taking his time in the role to over a decade.
Read moreAstraZeneca's Enhertu demonstrates 'statistically significant' survival rates in patients with breast cancer
21st Feb 2022 07:06
(Sharecast News) - Drugmaker AstraZeneca said its Enhurtu breast cancer drug had demonstrated a "statistically significant and clinically meaningful improvement" in survival a phase three trial versus chemotherapy.
Read moreAstraZeneca's Saphnelo receives EU approval
16th Feb 2022 07:10
(Sharecast News) - Drugmaker AstraZeneca revealed on Wednesday that Saphnelo had received European Union approval as an add-on therapy for the treatment of adult patients with moderate-to-severe, active autoantibody-positive systemic lupus erythematosus.
Read moreAstraZeneca's Lynparza delays progression risk in prostate cancer
15th Feb 2022 07:42
(Sharecast News) - Pharmaceutical company AstraZeneca said on Tuesday that results from a recent study revealed that its Lynparza asset reduced the risk of first-line metastatic castration-resistant prostate cancer progression by 34% when used in combination with abiraterone.
Read moreAstraZeneca raises dividend on growth prospects
10th Feb 2022 07:04
(Sharecast News) - AstraZeneca announced the first increase to its dividend for a decade and an upbeat outlook as the drugs company swung to a fourth-quarter loss driven by higher costs.
Read moreThursday preview: US CPI, AstraZeneca in focus
9th Feb 2022 18:32
(Sharecast News) - Investors' attention will be firmly on the latest consumer price due out in the US covering the month of January.
Read moreImmune system creates neutralising antibodies against Omicron after three exposures
7th Feb 2022 15:26
(Sharecast News) - German scientists have shown that the human immune system creates an abundant amount of high quality antibodies capable of neutralising Omicron once it has encountered the virus's spike protein three times.
Read more